Disease index

major depression

Mental health · 2007–2014

12decisions
6medicines
0carried consumer input
0individual submissions

No submission for this condition has carried consumer input, including the 2 made since the comments facility came into use.

Every decision

MedicineMeetingOutcomeConsumer input
escitalopram Major depressive disorder, moderate to severe generalised anxiety disorder, and moderate to severe social anxiety disorder. Jul 2014 Recommended none received
vortioxetine Treatment of major depressive disorder in patients who have received and not responded to an initial antidepressant medication or patients who are intolerant… Jul 2014 Recommended with restriction none received
quetiapine Recurrent major depressive disorder (MDD) as augmentation to current antidepressant therapy in patients with inadequate response to two prior antidepressant… Jul 2013 Not recommended no section in document
agomelatine Major depressive disorders in adults, including prevention of relapse. Mar 2012 Recommended unclear
agomelatine Major depressive disorders, including prevention of relapse. Mar 2012 Recommended unclear
agomelatine Major depressive disorders, including prevention of relapse in adults. Jul 2011 Not recommended unclear
agomelatine Major depressive disorder in adults, including prevention of relapse. Nov 2010 Recommended no section in document
duloxetine hydrochloride Treatment of major depressive disorder (MDD). Mar 2008 Recommended with restriction no section in document
duloxetine hydrochloride Treatment of major depressive disorder (MDD). Mar 2008 Recommended with restriction no section in document
desvenlafaxine succinate Treatment of major depressive disorder (MDD), including prevention of relapse. Nov 2008 Recommended with restriction no section in document
duloxetine hydrochloride Treatment of major depressive disorder. Jul 2007 Recommended no section in document
duloxetine hydrochloride Treatment of major depressive disorder. Jul 2007 Recommended no section in document

What the PBS pays

$98M in government benefit over 2024–25, across 6,661,767 services.

This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.

MedicineGovernment benefit
escitalopram $32M
desvenlafaxine succinate $24.4M
duloxetine hydrochloride $22.2M
quetiapine $19.3M

Appraised elsewhere

NICE, in England and Wales, has appraised 3 technologies for this condition, recommending 0 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.

TechnologyAppraisalOutcomeDate
esketamineEsketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal) TA899 terminated 2023-06
vortioxetineVortioxetine for treating major depressive episodes TA367 not recommended 2015-11
agomelatineAgomelatine for the treatment of major depressive episodes (terminated appraisal) TA231 terminated 2011-07

Registered, not subsidised

Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.

MedicineOn the ARTG sinceRegistrations
amitriptylineAMICHLOR amitriptyline hydrochloride 10mg tablet bottle pack 1997 97
citalopramA-CITALOPRAM citalopram (as hydrobromide) 20 mg tablet blister pack 1997 82
venlafaxineALEMBIC VENLAFAXINE XR venlafaxine (as hydrochloride) 150 mg modified 1998 69
mirtazapineAPO-MIRTAZAPINE mirtazapine 15 mg tablet bottle 2001 40
sertralineAPO-SERTRALINE sertraline (as hydrochloride) 100mg tablet blister pack 2003 38
paroxetineAPOTEX-PAROXETINE paroxetine 20mg (as hydrochloride) tablet blister pa 1997 22
moclobemideAMIRA 150 moclobemide 150 mg film-coated tablet blister pack 1991 20
nortriptylineALLEGRON nortriptyline (as hydrochloride) 10mg tablet blister pack 1991 16
fluoxetineAPO-FLUOXETINE 20mg fluoxetine (as hydrochloride) 20 mg capsules blist 1995 14
citalopram hydrobromideAPO-CITALOPRAM citalopram 40 mg (as hydrobromide) tablet blister pack 2010 10
fluvoxamineAPO-FLUVOXAMINE fluvoxamine maleate 100 mg tablet blister pack 1997 10
tranylcyprominePARNATE Tranylcypromine 10mg film coated tablet 2010 9
clomipramineAPO-CLOMIPRAMINE clomipramine hydrochloride 25mg tablet blister pack 1991 5
doxepinDEPTRAN 10 doxepin 10mg (as hydrochloride) capsule blister pack 1991 4
dosulepinDOSULEPIN VIATRIS 25 dosulepin (dothiepin) hydrochloride 25 mg hard ca 1991 4
reboxetineEDRONAX reboxetine 4mg (as mesilate) tablet blister pack 2001 2
imipramineTOFRANIL 10 imipramine hydrochloride 10mg tablet blister pack 1991 2
mianserinLUMIN 10 Mianserin Hydrochloride 10mg tablet 1996 2
phenelzineNARDIL phenelzine 15mg (as sulfate) tablet bottle 2024 1

The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.

Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.